Additional Information
Book Details
Abstract
Clinical Naturopathy: an evidence-based guide to practice, 2nd edition, E-book by Jerome Sarris and Jon Wardle, articulates evidence-based clinical practice.
It details the principles, treatment protocols and interventions at the forefront of naturopathic practice in the 21st century. Clinical Naturopathy: an evidence-based guide to practice 2e E-book, equips you to critically evaluate your patients, analyse treatment protocols, and provide evidence-based prescriptions.
This second edition promotes the fundamentals of traditional naturopathy, while pushing the scientific boundaries and driving the steady evolution of the profession of naturopathic medicine.
Perfect for:
Bachelor of Health Science (Naturopathy) Advanced diploma and Postgraduate students in:
- • Naturopathy
- • Western Herbal Medicine
- • Nutrition
- • Homoeopathy
Complementary health therapists General Practitioners Nursing students Pharmacy students
Benefits:
- • Provides an evidence-based, referenced analysis of the treatment protocols underpinning the therapeutic use of CAM interventions.
- • Emphasizes the treatment of patients not diseases within the systems based structure.
- • A rigorously researched update of common clinical conditions and their naturopathic treatment according to evidence-based guidelines (over 5,000 references).
- • Bridges conventional medical and naturopathic paradigms to help clinicians facilitate truly integrative models of care.
- • Augmented appendices including: herb/drug interaction charts, laboratory reference values, food sources of nutrients, cancer medication interactions and nutraceutical use.
- • Key Treatment Protocols throughout the text offer an evidence-based referenced critique.
- • Naturopathic Treatment trees for each condition, with Treatment Aims boxes that are easy to follow and understand.
- • Scientific and traditional evidence validating treatment protocols.
- • Decision trees, unique figures, tables and charts are a great aid to visual learners.
- • Expanded Diagnostics chapter including the emerging field of pharmacogenomics.
- • New Wellness, lifestyle and preventive medicine chapter to explore in detail the core principles of naturopathic practice.
- • New Liver dysfunction and disease, Headache and migraine, and Pain chapters.
- • A deepening scientific focus with inclusion of new and emerging naturopathic therapeutics such as injectable nutraceuticals.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Clinical Naturopathy: An Evidence-Based Guide to Practice | iii | ||
| Copyright Page | iv | ||
| Table of Contents | v | ||
| Foreword | vii | ||
| Preface | x | ||
| Acknowledgements | xii | ||
| About the Editors | xiii | ||
| Contributors | xiv | ||
| Reviewers | xvii | ||
| CHAPTER 1. Naturopathic case taking | 1 | ||
| OVERVIEW OF NATUROPATHIC PHILOSOPHY AND PRINCIPLES | 1 | ||
| PATIENT-CENTRED APPROACH TO HOLISTIC CONSULTATION | 5 | ||
| POSOLOGY | 12 | ||
| SIGNPOSTS FOR RECOVERY | 13 | ||
| CASE TAKING: THE RETURN VISIT | 14 | ||
| CASE TAKING: ADVANCED | 15 | ||
| KEY POINTS | 17 | ||
| FURTHER READING | 17 | ||
| REFERENCES | 17 | ||
| CHAPTER 2. Naturopathic diagnostic techniques | 19 | ||
| OVERVIEW | 19 | ||
| CLINICAL DIAGNOSTIC TECHNIQUES | 20 | ||
| STANDARD MEDICAL PATHOLOGY TESTING | 28 | ||
| FUNCTIONAL PATHOLOGY TESTING | 30 | ||
| NUTRIGENETIC AND GENOMIC TECHNOLOGIES | 34 | ||
| FACTORS AFFECTING NUTRITIONAL STATUS | 37 | ||
| CHOOSING DIAGNOSTIC METHODS | 44 | ||
| KEY POINTS | 45 | ||
| FURTHER READING | 46 | ||
| REFERENCES | 46 | ||
| CHAPTER 3. Wellness, lifestyle and preventive medicine | 53 | ||
| OVERVIEW | 53 | ||
| THE PHILOSOPHY OF WELLNESS | 54 | ||
| PUBLIC HEALTH PERSPECTIVE | 65 | ||
| KEY POINTS | 68 | ||
| FURTHER READING | 69 | ||
| REFERENCES | 69 | ||
| CHAPTER 4. Irritable bowel syndrome | 73 | ||
| OVERVIEW | 73 | ||
| RISK FACTORS | 74 | ||
| CONVENTIONAL TREATMENT | 75 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 87 | ||
| CLINICAL SUMMARY | 88 | ||
| KEY POINTS | 93 | ||
| FURTHER READING | 93 | ||
| REFERENCES | 93 | ||
| CHAPTER 5. Gastro-oesophageal reflux disease | 101 | ||
| OVERVIEW | 101 | ||
| RISK FACTORS | 103 | ||
| CONVENTIONAL TREATMENT | 104 | ||
| KEY TREATMENT PROTOCOLS | 104 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 109 | ||
| CLINICAL SUMMARY | 109 | ||
| KEY POINTS | 114 | ||
| FURTHER READING | 114 | ||
| REFERENCES | 114 | ||
| CHAPTER 6. Food allergy/intolerance | 118 | ||
| OVERVIEW | 118 | ||
| RISK FACTORS | 119 | ||
| CONVENTIONAL TREATMENT | 120 | ||
| KEY TREATMENT PROTOCOLS | 121 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 125 | ||
| CLINICAL SUMMARY | 125 | ||
| KEY POINTS | 126 | ||
| FURTHER READING | 128 | ||
| REFERENCES | 128 | ||
| CHAPTER 7. Liver dysfunction and disease | 130 | ||
| OVERVIEW | 130 | ||
| NON-ALCOHOLIC FATTY LIVER DISEASE | 132 | ||
| OTHER LIVER AND BILIARY DISEASES | 144 | ||
| KEY POINTS | 152 | ||
| FURTHER READING | 152 | ||
| REFERENCES | 152 | ||
| CHAPTER 8. Respiratory infections and immune insufficiency | 159 | ||
| OVERVIEW | 159 | ||
| CONVENTIONAL TREATMENT | 161 | ||
| KEY TREATMENT PROTOCOLS | 162 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 173 | ||
| CLINICAL SUMMARY | 173 | ||
| KEY POINTS | 177 | ||
| FURTHER READING | 177 | ||
| REFERENCES | 177 | ||
| CHAPTER 9. Asthma | 183 | ||
| OVERVIEW | 183 | ||
| RISK FACTORS | 185 | ||
| CONVENTIONAL TREATMENT | 186 | ||
| KEY TREATMENT PROTOCOLS | 187 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 195 | ||
| CLINICAL SUMMARY | 195 | ||
| KEY POINTS | 199 | ||
| FURTHER READING | 199 | ||
| REFERENCES | 199 | ||
| CHAPTER 10. Congestive respiratory disorders | 205 | ||
| OVERVIEW | 205 | ||
| RISK FACTORS | 206 | ||
| CONVENTIONAL TREATMENT | 206 | ||
| KEY TREATMENT PROTOCOLS | 206 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 216 | ||
| CLINICAL SUMMARY | 216 | ||
| KEY POINTS | 219 | ||
| FURTHER READING | 219 | ||
| REFERENCES | 219 | ||
| CHAPTER 11. Atherosclerosis and dyslipidaemia | 224 | ||
| OVERVIEW | 224 | ||
| RISK FACTORS | 227 | ||
| CONVENTIONAL TREATMENT | 228 | ||
| KEY TREATMENT PROTOCOLS | 230 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 234 | ||
| CLINICAL SUMMARY | 235 | ||
| KEY POINTS | 240 | ||
| FURTHER READING | 240 | ||
| REFERENCES | 240 | ||
| CHAPTER 12. Hypertension and stroke | 243 | ||
| OVERVIEW | 243 | ||
| RISK FACTORS | 244 | ||
| CONVENTIONAL TREATMENT | 245 | ||
| KEY TREATMENT PROTOCOLS | 246 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 250 | ||
| CLINICAL SUMMARY | 251 | ||
| KEY POINTS | 254 | ||
| FURTHER READING | 254 | ||
| REFERENCES | 254 | ||
| CHAPTER 13. Chronic venous insufficiency | 257 | ||
| OVERVIEW | 257 | ||
| RISK FACTORS | 257 | ||
| CONVENTIONAL TREATMENT | 258 | ||
| KEY TREATMENT PROTOCOLS | 259 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 261 | ||
| CLINICAL SUMMARY | 264 | ||
| KEY POINTS | 267 | ||
| FURTHER READING | 267 | ||
| REFERENCES | 267 | ||
| CHAPTER 14. Anxiety | 270 | ||
| OVERVIEW | 270 | ||
| RISK FACTORS | 272 | ||
| CONVENTIONAL TREATMENT | 272 | ||
| KEY TREATMENT PROTOCOLS | 273 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 279 | ||
| CLINICAL SUMMARY | 282 | ||
| KEY POINTS | 287 | ||
| FURTHER READING | 287 | ||
| REFERENCES | 287 | ||
| CHAPTER 15. Depression | 291 | ||
| OVERVIEW | 291 | ||
| RISK FACTORS | 292 | ||
| CONVENTIONAL TREATMENT | 294 | ||
| KEY TREATMENT PROTOCOLS | 294 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 301 | ||
| CLINICAL SUMMARY | 304 | ||
| KEY POINTS | 309 | ||
| FURTHER READING | 309 | ||
| REFERENCES | 309 | ||
| CHAPTER 16. Insomnia | 313 | ||
| OVERVIEW | 313 | ||
| RISK FACTORS | 314 | ||
| CONVENTIONAL TREATMENT | 315 | ||
| KEY TREATMENT PROTOCOLS | 316 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 320 | ||
| CLINICAL SUMMARY | 322 | ||
| KEY POINTS | 325 | ||
| FURTHER READING | 325 | ||
| REFERENCES | 325 | ||
| CHAPTER 17. Headache and migraine | 328 | ||
| OVERVIEW | 328 | ||
| CONVENTIONAL TREATMENT | 329 | ||
| KEY TREATMENT PROTOCOLS | 334 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 340 | ||
| CLINICAL SUMMARY | 341 | ||
| KEY POINTS | 345 | ||
| FURTHER READING | 345 | ||
| REFERENCES | 345 | ||
| CHAPTER 18. Stress and fatigue | 350 | ||
| OVERVIEW | 350 | ||
| RISK FACTORS | 357 | ||
| CONVENTIONAL TREATMENT | 357 | ||
| KEY TREATMENT PROTOCOLS | 357 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 362 | ||
| CLINICAL SUMMARY | 363 | ||
| KEY POINTS | 367 | ||
| FURTHER READING | 367 | ||
| REFERENCES | 367 | ||
| CHAPTER 19. Diabetes type 2 and insulin resistance | 371 | ||
| OVERVIEW | 371 | ||
| RISK FACTORS | 376 | ||
| CONVENTIONAL MEDICATION | 377 | ||
| KEY TREATMENT PROTOCOLS | 379 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 388 | ||
| CLINICAL SUMMARY | 388 | ||
| KEY POINTS | 393 | ||
| FURTHER READING | 393 | ||
| REFERENCES | 393 | ||
| CHAPTER 20. Thyroid abnormalities | 399 | ||
| OVERVIEW | 399 | ||
| RISK FACTORS | 404 | ||
| CONVENTIONAL TREATMENT | 408 | ||
| KEY TREATMENT PROTOCOLS | 409 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 414 | ||
| CLINICAL SUMMARY | 415 | ||
| KEY POINTS | 418 | ||
| FURTHER READING | 418 | ||
| REFERENCES | 418 | ||
| CHAPTER 21. Dysmenorrhoea and menstrual complaints | 423 | ||
| OVERVIEW | 423 | ||
| RISK FACTORS | 425 | ||
| CONVENTIONAL TREATMENT | 426 | ||
| KEY TREATMENT PROTOCOLS | 426 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 429 | ||
| CLINICAL SUMMARY | 431 | ||
| KEY POINTS | 435 | ||
| FURTHER READING | 435 | ||
| REFERENCES | 435 | ||
| CHAPTER 22. Endometriosis | 439 | ||
| OVERVIEW | 439 | ||
| RISK FACTORS | 440 | ||
| CONVENTIONAL TREATMENT | 440 | ||
| KEY TREATMENT PROTOCOLS | 440 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 446 | ||
| CLINICAL SUMMARY | 446 | ||
| KEY POINTS | 449 | ||
| FURTHER READING | 449 | ||
| REFERENCES | 449 | ||
| CHAPTER 23. Polycystic ovarian syndrome | 452 | ||
| OVERVIEW | 452 | ||
| RISK FACTORS | 454 | ||
| CONVENTIONAL TREATMENT | 454 | ||
| DIAGNOSTIC TEMPERATURE CHARTING | 455 | ||
| KEY TREATMENT PROTOCOLS | 456 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 462 | ||
| CLINICAL SUMMARY | 463 | ||
| KEY POINTS | 466 | ||
| FURTHER READING | 466 | ||
| REFERENCES | 466 | ||
| CHAPTER 24. Menopause | 470 | ||
| OVERVIEW | 470 | ||
| RISK FACTORS | 471 | ||
| CONVENTIONAL TREATMENT | 472 | ||
| KEY TREATMENT PROTOCOLS | 474 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 480 | ||
| CLINICAL SUMMARY | 480 | ||
| KEY POINTS | 484 | ||
| FURTHER READING | 484 | ||
| REFERENCES | 484 | ||
| CHAPTER 25. Osteoarthritis | 487 | ||
| OVERVIEW | 487 | ||
| RISK FACTORS | 489 | ||
| CONVENTIONAL TREATMENT | 490 | ||
| KEY TREATMENT PROTOCOLS | 491 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 499 | ||
| CLINICAL SUMMARY | 500 | ||
| KEY POINTS | 504 | ||
| FURTHER READING | 504 | ||
| REFERENCES | 504 | ||
| CHAPTER 26. Fibromyalgia | 507 | ||
| OVERVIEW | 507 | ||
| RISK FACTORS | 507 | ||
| CONVENTIONAL TREATMENT | 508 | ||
| KEY TREATMENT PROTOCOLS | 511 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 516 | ||
| CLINICAL SUMMARY | 521 | ||
| KEY POINTS | 525 | ||
| FURTHER READING | 525 | ||
| REFERENCES | 525 | ||
| CHAPTER 27. Acne vulgaris | 529 | ||
| OVERVIEW | 529 | ||
| RISK FACTORS | 530 | ||
| CONVENTIONAL TREATMENT | 530 | ||
| KEY TREATMENT PROTOCOLS | 531 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 536 | ||
| CLINICAL SUMMARY | 537 | ||
| KEY POINTS | 540 | ||
| FURTHER READING | 540 | ||
| REFERENCES | 540 | ||
| CHAPTER 28. Inflammatory skin disorders—atopic eczema and psoriasis | 543 | ||
| OVERVIEW | 543 | ||
| RISK FACTORS | 544 | ||
| CONVENTIONAL TREATMENT | 544 | ||
| KEY TREATMENT PROTOCOLS | 546 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 552 | ||
| CLINICAL SUMMARY | 553 | ||
| KEY POINTS | 556 | ||
| FURTHER READING | 556 | ||
| REFERENCES | 556 | ||
| CHAPTER 29. Benign prostatic hypertrophy | 558 | ||
| OVERVIEW | 558 | ||
| RISK FACTORS | 560 | ||
| CONVENTIONAL TREATMENT | 560 | ||
| KEY TREATMENT PROTOCOLS | 561 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 568 | ||
| CLINICAL SUMMARY | 568 | ||
| KEY POINTS | 574 | ||
| FURTHER READING | 574 | ||
| REFERENCES | 574 | ||
| CHAPTER 30. Recurrent urinary tract infection | 578 | ||
| OVERVIEW | 578 | ||
| RISK FACTORS | 579 | ||
| CONVENTIONAL TREATMENT | 579 | ||
| KEY TREATMENT PROTOCOLS | 579 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 585 | ||
| CLINICAL SUMMARY | 585 | ||
| KEY POINTS | 591 | ||
| FURTHER READING | 591 | ||
| REFERENCES | 591 | ||
| CHAPTER 31. Autoimmune disease | 593 | ||
| OVERVIEW | 593 | ||
| DIFFERENTIAL DIAGNOSIS | 597 | ||
| RISK FACTORS | 598 | ||
| CONVENTIONAL TREATMENT | 599 | ||
| KEY TREATMENT PROTOCOLS | 600 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 610 | ||
| SPECIFIC AUTOIMMUNE DISORDERS | 612 | ||
| CLINICAL SUMMARY | 619 | ||
| KEY POINTS | 623 | ||
| FURTHER READING | 623 | ||
| REFERENCES | 623 | ||
| CHAPTER 32. Cancer | 629 | ||
| OVERVIEW | 629 | ||
| RISK FACTORS | 630 | ||
| DIFFERENTIAL DIAGNOSIS | 630 | ||
| CONVENTIONAL TREATMENT | 632 | ||
| KEY TREATMENT PROTOCOLS | 635 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 641 | ||
| CLINICAL SUMMARY | 646 | ||
| KEY POINTS | 648 | ||
| FURTHER READING | 648 | ||
| REFERENCES | 648 | ||
| CHAPTER 33. Paediatrics | 655 | ||
| OVERVIEW | 655 | ||
| COMPLIANCE ISSUES | 662 | ||
| EXAMPLES OF TREATMENT FOR COMMON PAEDIATRIC CONDITIONS | 663 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 668 | ||
| CLINICAL SUMMARY | 669 | ||
| KEY POINTS | 671 | ||
| FURTHER READING | 671 | ||
| REFERENCES | 671 | ||
| CHAPTER 34. Fertility, preconception care and pregnancy | 673 | ||
| OVERVIEW—PRECONCEPTION CARE | 673 | ||
| INFERTILITY AND SUBFERTILITY | 680 | ||
| RISK FACTORS | 681 | ||
| KEY TREATMENT PROTOCOLS | 682 | ||
| CONVENTIONAL TREATMENT | 683 | ||
| OVERVIEW—PREGNANCY | 685 | ||
| POSTNATAL SUPPORT | 693 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 694 | ||
| CLINICAL SUMMARY | 695 | ||
| KEY POINTS | 701 | ||
| FURTHER READING | 701 | ||
| REFERENCES | 701 | ||
| CHAPTER 35. Ageing and cognition | 708 | ||
| OVERVIEW | 708 | ||
| RISK FACTORS | 713 | ||
| CONVENTIONAL TREATMENT | 714 | ||
| KEY TREATMENT PROTOCOLS | 714 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 719 | ||
| CLINICAL SUMMARY | 721 | ||
| KEY POINTS | 726 | ||
| FURTHER READING | 726 | ||
| REFERENCES | 726 | ||
| CHAPTER 36. Bipolar disorder | 731 | ||
| OVERVIEW | 731 | ||
| RISK FACTORS | 733 | ||
| CONVENTIONAL TREATMENT | 734 | ||
| INTEGRATIVE MEDICAL TREATMENT OPTIONS | 735 | ||
| CLINICAL SUMMARY | 741 | ||
| KEY POINTS | 746 | ||
| FURTHER READING | 746 | ||
| REFERENCES | 746 | ||
| CHAPTER 37. Attention deficit and hyperactivity disorder | 750 | ||
| RISK FACTORS | 751 | ||
| CONVENTIONAL TREATMENT | 752 | ||
| INTEGRATIVE MEDICAL TREATMENT OPTIONS | 753 | ||
| CLINICAL SUMMARY | 759 | ||
| KEY POINTS | 764 | ||
| FURTHER READING | 764 | ||
| REFERENCES | 764 | ||
| CHAPTER 38. Chronic fatigue syndrome | 768 | ||
| OVERVIEW | 768 | ||
| RISK FACTORS | 771 | ||
| CONVENTIONAL TREATMENT | 771 | ||
| KEY TREATMENT PROTOCOLS | 772 | ||
| INJECTABLE NUTRACEUTICALS | 777 | ||
| CLINICAL SUMMARY | 779 | ||
| KEY POINTS | 784 | ||
| FURTHER READING | 785 | ||
| REFERENCES | 785 | ||
| CHAPTER 39. Human immunodeficiency virus | 789 | ||
| OVERVIEW | 789 | ||
| RISK FACTORS | 789 | ||
| CONVENTIONAL TREATMENT | 790 | ||
| KEY TREATMENT PROTOCOLS | 790 | ||
| CLINICAL SUMMARY | 796 | ||
| KEY POINTS | 800 | ||
| FURTHER READING | 800 | ||
| REFERENCES | 800 | ||
| CHAPTER 40. Pain management | 803 | ||
| OVERVIEW | 803 | ||
| RISK FACTORS | 807 | ||
| CONVENTIONAL TREATMENT | 808 | ||
| KEY TREATMENT PROTOCOLS | 809 | ||
| INTEGRATIVE MEDICAL CONSIDERATIONS | 814 | ||
| CLINICAL SUMMARY | 815 | ||
| KEY POINTS | 817 | ||
| FURTHER READING | 817 | ||
| REFERENCES | 817 | ||
| CHAPTER 41. Polypharmacy and drug–nutraceutical interactions | 823 | ||
| OVERVIEW | 823 | ||
| PHARMACOKINETIC INTERACTIONS | 824 | ||
| PHARMACODYNAMIC INTERACTIONS | 830 | ||
| PHYSICOCHEMICAL INTERACTIONS | 831 | ||
| FURTHER READING | 836 | ||
| REFERENCES | 836 | ||
| APPENDIX 1: Drug–herb interaction chart | 839 | ||
| REFERENCES | 844 | ||
| APPENDIX 2: Drug–nutrient interaction chart | 845 | ||
| REFERENCES | 851 | ||
| APPENDIX 3: Chemotherapy drugs and concurrent nutraceutical use | 852 | ||
| REFERENCES | 871 | ||
| APPENDIX 4: Food sources of nutrients | 877 | ||
| APPENDIX 5: Laboratory reference values | 879 | ||
| APPENDIX 6: Taxonomic cross-reference of major herbs | 887 | ||
| Index | 895 |